PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Sugammadex

Drugs in development · updated 30 October 2026

Sugammadex: clinical trials and development status

Other names and codes: Bridion

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 25 July 2008

As of 30 October 2026 Sugammadex is in 3 active clinical trials (recruiting or ongoing, phases I–III) for 0 diseases. The most advanced phase is III.

3Active trials
IIIMost advanced phase
0Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Sugammadex and get an email at every change or safety alert.

Sign in free →

Everything on Sugammadex

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch